Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Cash from Financing Activities (2016 - 2025)

Mimedx's Cash from Financing Activities history spans 15 years, with the latest figure at -$583000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 45.75% year-over-year to -$583000.0; the TTM value through Dec 2025 reached -$5.4 million, up 84.17%, while the annual FY2025 figure was -$5.4 million, 84.17% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$583000.0 at Mimedx, up from -$857000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $370000.0 in Q3 2023 and bottomed at -$33.5 million in Q1 2024.
  • The 5-year median for Cash from Financing Activities is -$379500.0 (2024), against an average of -$2.6 million.
  • The largest annual shift saw Cash from Financing Activities soared 200.0% in 2022 before it plummeted 836575.0% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $22000.0 in 2021, then skyrocketed by 200.0% to $66000.0 in 2022, then crashed by 13645.45% to -$8.9 million in 2023, then soared by 95.53% to -$400000.0 in 2024, then tumbled by 45.75% to -$583000.0 in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Cash from Financing Activities are -$583000.0 (Q4 2025), -$857000.0 (Q3 2025), and -$1.1 million (Q2 2025).